In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy

Nuclear Medicine and Biology

Volumn 32, Issue 3, 2005, Pages 233-239

  Cornelissen, Bart ^a   Lahorte, Christophe ^a   Kersemans, Veerle ^a   Capriotti, Gabriela ^b   Bonanno, Elena ^c   Signore, Alberto ^b   Van De Wiele, Christophe ^d   Dierckx, Rudi A ^d   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

^b POLICLINICO UMBERTO I   (Italy)

^c UNIVERSITY OF ROME G MARCONI   (Italy)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Annexin V; Apoptosis; Farnesyl transferase inhibitor; Oncology; Tipifarnib

Indexed keywords

BETA CYCLODEXTRIN; HYDROCHLORIC ACID; IODINE 123; LIPOCORTIN 5; LIPOCORTIN 5 I 123; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG UPTAKE; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; INOCULATION; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PREDICTION; RADIOIODINATION; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; XENOGRAFT;

EID: 16844377487     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.01.001     Document Type: Article

References (31)

1. A.A. Adjei Blocking oncogenic Ras signalling for cancer therapy J. Natl. Cancer Inst. 93 2001 1062 1074
2. R.E. Favoni, and A. De Cupis The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach Pharmacol. Rev. 52 2000 179 206
3. H.R. Ashar, L. James, K. Gray, D. Carr, S. Black, and L. Armstrong Farnesyltransferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with mictotubules J. Biol. Chem. 275 2000 30451 30457
4. T.B. Brunner, S.M. Hahn, A.K. Gupta, R.J. Muschel, W.G. McKenna, and E.J. Bernhard Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations Cancer Res. 63 2003 5656 5668
5. Z. Chen, J. Sun, A. Pradines, G. Favre, J. Adnane, and S.M. Sebti Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice J. Biol. Chem. 275 2000 17974 17978
6. A.D. Cox Farnesyltransferase inhibitors. Potential role in the treatment of cancer Drugs 61 2001 726 732
7. K. Jiang, D. Coppola, N.C. Crespo, S.V. Nicosia, A.D. Hamilton, and S.M. Sebti The phosphoinositide 3-OH kinase/Akt2 pathway as a critical target for farnesyltranferase inhibitor-induced apoptosis Mol. Cell Biol. 20 2000 139 148
8. G.C. Prendergast Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects Curr. Opin. Cell Biol. 12 2000 166 173
9. N. Suzuki, K. Keith Del Villar, and F. Tamanoi Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents Proc. Natl. Acad. Sci. U. S. A. 95 1998 10499 10504
10. F. Tamanoi, C.-L. Gau, C. Jiang, H. Edamatsu, and J. Kato-Stankiewicz Protein farnesylation in mammalian cells: Effects of farnesyltransferase inhibitors on cancer cells Cell. Mol. Life Sci. 58 2001 1636 1649
11. P.Z. Lebowitz, D. Sakamuro, and G.C. Prendergast Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment Cancer Res. 57 1998 708 713
12. N. Suzuki, J. Urano, and F. Tamanoi Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells Proc. Natl. Acad. Sci. U. S. A. 95 1998 15356 15361
13. D.M. Beaupre, E. Cepero, E.A. Obeng, L.H. Boise, and M.G. Lichtenheld R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways Mol. Cancer Ther. 3 2004 179 186
14. D.W. End, G. Smets, A.V. Todd, T.L. Applegate, C.J. Fuery, and P. Angibaud Characterisation of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res. 6 2001 131 137
15. L. Sepp-Lorenzino, and N. Rosen A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis Mol. Cell. Biol. 18 1998 85 92
16. B. Zhang, G.C. Prendergast, and R.G. Fenton Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression Cancer Res. 62 2002 450 458
17. B. Cornelissen, A. Allaert, and G. Slegers Radioiodinated IGF-I as a possible biomarker for monitoring the effect of the farnesyl transferase inhibitor R115777 Eur. J. Nucl. Med. Mol. Imaging 30 2003 S191
18. B. Cornelissen, V. Kersemans, C. Vandewiele, R.A. Dierckx, and G. Slegers A rapid in vivo diagnostical assay to assess the effect of a farnesyl transferase inhibitor on LoVo cells using 123I-hEGF Cancer Biother. Radiopharm. 18 2003 283
19. B. Cornelissen, K. Remaut, V. Kersemans, R. Oltenfreiter, I. Burvenich, and G. Slegers 123I-EGF internalisation in tumour cells in vitro is inhibited by farnesyltransferase inhibitor therapy: Possible target for early therapy response prediction Eur. J. Nucl. Med. Mol. Imaging 31 2004 S391
20. B. Cornelissen, T. Thonissen, V. Kersemans, C. Van de Wiele, C. Lahorte, and R.A. Dierckx Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status Nucl. Med. Biol. 31 2004 679 689
21. C.M.M. Lahorte, J.L. Vanderheyden, N. Steinmetz, C. Van de Wiele, R.A. Dierckx, and G. Slegers Apoptosis-detecting radioligands: Current state of the art and future perspectives Eur. J. Nucl. Med. Mol. Imaging 31 2004 887 919
22. M. Brauer In vivo monitoring of apoptosis Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 323 331
23. T.R. Allen, W.J. Hunter III, and D.K. Agrawal Morphological and biochemical characterization and analysis of apoptosis J. Pharmacol. Toxicol. Methods 37 1997 215 228
24. G.F. Blankenberg, P. Katsikis, J. Tait, R.E. Davis, L. Naumovski, and K. Obtsuki In vivo detection and imaging of phosphaditylserine expression during programmed cell death Proc. Natl. Acad. Sci. U. S. A. 95 1998 6349 6354
25. 123I-labelled Annexin V: A potential agent for SPECT imaging of apoptotic cells J. Label. Compd. Radiopharm. 43 2000 739 750
26. S.P. Modak, and F.J. Bollum Terminal lens cell differentiation Exp. Cell Res. 62 1970 421 432
27. D.B. Bylund, and H.I. Yamamura Methods for receptor binding D.B. Bylund H.I. Yamamura Methods in neurotransmitter receptor analysis 1990 Raven New York 1 35
28. A.B. Cairnie, and K.E. Leach Quantitative studies of cytological damage in mouse testis produced by exposure to heat Can. J. Genet. Cytol. 22 1980 93 102
29. Cornelissen B, Kersemans V, Jans L, Staelens L, Oltenfreiter R, Thonissen T, et al. Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice. Br J Radiol [accepted for publication].
30. C. Lahorte, C. Van de Wiele, K. Bacher, B. Van den Bossche, H. Thierens, and S. Van Belle Biodistribution and dosimetry study of 123I-rh-Annexin V in mice and humans Nucl. Med. Commun. 24 2003 871 880
31. C. Van de Wiele, C. Lahorte, H. Vermeersch, D. Loose, K. Mervillie, and N.D. Steinmetz Quantitative tumour apoptosis imaging using 99mTc-HYNIC-Annexin V single photon emission computerized tomography Clin. J. Oncol. 21 2003 2483 2487